Close
Almac
Achema middle east

$15m Mitochondrial Clinical Trial Headed by Australian University

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -

Almost 50 children in Australia are born every year with a devastating mitochondrial disease that has an expected lifespan of just 5 years. In a first in Australia, the Medical Research Future Fund has gone on to announce $15 million in funding, which also happens to be only the second in the world when it comes to clinical trials of mitochondrial donation.

The mitochondrial DNA is inherited through the mother’s egg and is responsible when it comes to helping mitochondria generate energy across all the body’s cells. Apparently, if the mitochondrial DNA carries variants that lead to energy production that is indeed faulty, mitochondrial disease can be caused.

Mitochondrial donations look forward to rectifying this genetic timebomb through an assisted reproductive technology form under which the future baby’s mitochondrial DNA is available from a donor’s egg so as to avoid the passing of the torch when it comes to inherited mitochondrial disease.

The mitoHOPE, which stands for Healthy Outcomes Pilot and Evaluation Programme, has in it mitochondrial as well as clinical geneticists from across the country, as well as fertility specialists and clinical embryologists from Monash IVF, who happen to be working together with Monash University’s and the University of Adelaide’s reproductive scientists.

It is well to be noted that the trial, which happens to be based in Melbourne in partnership with Monash, is going to be available for all the eligible women from across the country.

Apparently, the success of the mitoHOPE programme will be completely dependent on the Australian women’s willingness when it comes to donating eggs for reproductive purposes and also for research use so as to make improvements in the technical procedures.

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »